- Home
- LGCL vs VYNE Comparison
LGCL vs VYNE Comparison
Compare LGCL & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- VYNE
- Stock Information
- Founded
- LGCL 2009
- VYNE 2003
- Country
- LGCL China
- VYNE United States
- Employees
- LGCL N/A
- VYNE N/A
- Industry
- LGCL
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- LGCL
- VYNE Health Care
- Exchange
- LGCL NYSE
- VYNE Nasdaq
- Market Cap
- LGCL 39.7M
- VYNE 35.7M
- IPO Year
- LGCL 2024
- VYNE 2018
- Fundamental
- Price
- LGCL $0.55
- VYNE $1.00
- Analyst Decision
- LGCL
- VYNE Strong Buy
- Analyst Count
- LGCL 0
- VYNE 2
- Target Price
- LGCL N/A
- VYNE $6.25
- AVG Volume (30 Days)
- LGCL 73.9K
- VYNE 274.1K
- Earning Date
- LGCL 01-01-0001
- VYNE 05-08-2025
- Dividend Yield
- LGCL N/A
- VYNE N/A
- EPS Growth
- LGCL N/A
- VYNE N/A
- EPS
- LGCL 0.07
- VYNE N/A
- Revenue
- LGCL $145,690,427.00
- VYNE $605,000.00
- Revenue This Year
- LGCL N/A
- VYNE N/A
- Revenue Next Year
- LGCL N/A
- VYNE N/A
- P/E Ratio
- LGCL $8.03
- VYNE N/A
- Revenue Growth
- LGCL N/A
- VYNE 43.03
- 52 Week Low
- LGCL $0.28
- VYNE $0.91
- 52 Week High
- LGCL $3.31
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- VYNE 32.67
- Support Level
- LGCL N/A
- VYNE $0.96
- Resistance Level
- LGCL N/A
- VYNE $1.09
- Average True Range (ATR)
- LGCL 0.00
- VYNE 0.08
- MACD
- LGCL 0.00
- VYNE -0.00
- Stochastic Oscillator
- LGCL 0.00
- VYNE 21.41
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.